Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% Higher – What’s Next?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s share price rose 6.5% during mid-day trading on Thursday . The company traded as high as $11.42 and last traded at $11.6540. Approximately 66,428 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 662,627 shares. The stock had previously closed at $10.94.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Bank of America lifted their target price on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. JPMorgan Chase & Co. began coverage on Fulcrum Therapeutics in a research note on Monday, January 12th. They set an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Piper Sandler restated an “overweight” rating and set a $23.00 price target (up from $16.00) on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.11.

Fulcrum Therapeutics Price Performance

The company has a market capitalization of $638.99 million, a P/E ratio of -10.08 and a beta of 3.19. The company has a 50 day moving average of $10.97 and a 200-day moving average of $9.36.

Insider Buying and Selling

In related news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 63.5% during the 2nd quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock valued at $3,871,000 after buying an additional 218,819 shares in the last quarter. Bailard Inc. bought a new position in shares of Fulcrum Therapeutics in the 2nd quarter worth about $185,000. Campbell & CO Investment Adviser LLC purchased a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $943,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Fulcrum Therapeutics by 57.3% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock worth $2,357,000 after acquiring an additional 124,798 shares in the last quarter. Finally, Integrated Quantitative Investments LLC bought a new stake in Fulcrum Therapeutics during the second quarter worth about $283,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.